Happiest Minds Technologies

Valuation can remain elevated

We met the management of Happiest Minds (HAPPSTMN) and believe that the company has growth catalysts despite services being more discretionary. The company is transitioning from an EduTech-heavy portfolio to a higher mix of BFSI and Healthcare (larger spending pool and pipeline)-recent acquisitions will accelerate growth prospects in the vertical with the up-sell opportunity. HAPPSTMN reiterated its long-term ambition to reach USD 1bn over the next eight years (23% CAGR including inorganic) – FY25E revenue growth outlook is 35 to 40% (including inorganic Pure Software & Aureus, implying organic at 10-15%). HAPPSTMN has recently changed its organisational structure and moved to an industry/vertical structure (Happiest Minds - Organisational rejig for better growth). We continue to believe that the current scale of the business, the distinction in quality and the disproportionate impact from potential recovery in discretionary services in the sector can keep valuation higher than peers for HAPPSTMN. We factor USD revenue growth at 34% and 26% for FY25E and FY26E respectively; factor EBITM at 16.1% and 17.8%, translating to an EPS CAGR of 27% over FY24-26E-maintain ADD with TP of INR 900, at 36x FY26E EPS.

GenAI growth driver: HAPPSTMN has set up GenAI business unit (GBS) as compared to peers that have predominantly set up a Center of Excellence (CoE) in GenAI. The GBS unit which currently includes 80 employees is expected to scale to 250 employees over the next year. Currently, the project size in GenAI is USD 150-250k and includes opportunities in contextual chatbots, learning simulators, sentiment analysis, and content generation. GenAI is also expanding the company's geography base in regions such as APAC.

EduTech may lag growth: HAPPSTMN's EduTech vertical contributes 22% to the revenue and includes a diverse set of clients largely in the US geography. HAPPSTMN is a strategic vendor for its large clients in the vertical. In the EduTech segment, competition is also from tier-1 IT peers. EduTech vertical is expected to grow below the company average over the medium term (likely 5-10% organic), which is also influenced by client concentration.

Scale up in Healthcare and India business: HAPPSTMN has scaled its healthcare vertical from 4-5% of revenue in FY22 to 16% of revenue or USD 30mn+ revenue rate and the company has invested in building capabilities in areas such as bioinformatics. This is likely to get to USD 50mn revenue run-rate business, following the consolidation of the Pure Software acquisition. The scale-up in the vertical was supported inorganically with the acquisition of SMI (USD 10mn revenue) and also improved the offshore delivery network of the company. HAPPSTMN has supported key projects such as the setup of a Security Operations Center (SOC) for India's leading telco. Several large Indian automotive OEMs and universities feature in the company's client roster.

Financial Summary

i manetar o ammury						
YE March (INR bn)	FY21	FY22	FY23	FY24	FY25E	FY26E
Revenue (USD mn)	104	147	178	196	263	331
Net Sales	7.73	10.94	14.29	16.25	21.95	28.09
EBIT	1.69	2.25	3.17	2.78	3.54	4.99
APAT	1.62	1.86	2.36	2.38	2.72	3.81
Diluted EPS (INR)	10.7	12.2	15.5	15.6	17.9	25.0
P/E (x)	82.9	72.5	57.1	56.6	49.4	35.3
EV / EBITDA (x)	68.3	50.5	36.9	37.4	28.8	21.1
RoE (%)	40.0	30.6	31.3	20.5	17.4	21.5

Source: Company, HSIE Research



ADD

FY26E

+2.9

CMP (as on 18	INR 884		
Target Price	INR 900		
NIFTY	23,558		
KEY CHANGES	OLD	NEW	
	OLD ADD	NEW ADD	

FY25E

-1.7

KEY STOCK DATA

EPS %

Bloomberg code	HAPPSTMN IN
No. of Shares (mn)	152
MCap (INR bn) / (\$ mn	.) 137/1,614
6m avg traded value (II	NR mn) 467
52 Week high / low	INR 1,023/738

STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	12.3	(5.6)	(2.6)
Relative (%)	5.9	(13.7)	(24.6)

SHAREHOLDING PATTERN (%)

	Dec-23	Mar-24
Promoters	50.24	50.24
FIs & Local MFs	2.41	2.57
FPIs	5.05	4.69
Public & Others	42.30	42.50
Pledged Shares	3.60	3.60
Source : BSE		

Apurva Prasad

apurva.prasad@hdfcsec.com +91-22-6171-7327

Amit Chandra

amit.chandra@hdfcsec.com +91-22-6171-7345

Vinesh Vala

vinesh.vala@hdfcsec.com +91-22-6171-7332



Pure Software acquisition: The acquisition rationale is to build depth in industry verticals - BFSI and Healthcare, cross-sell opportunity into marquee logos (Prudential, S&P etc.), banking as a service platform (Arttha) and access nearshore delivery centers of Mexico.

Key highlights include: (1) Pure Software was acquired by the company for a purchase consideration of USD 94.5mn (including upfront USD 77mn and an earnout of USD 17mn in a year) at 2.2x revenue (including earn-out) and approx. 12x EBITDA. (2) Pure Software is a software product engineering and IT services company headquartered in Noida with global operations and 1,200 employees. (3) It operates in verticals of BFSI, Lifescience, and Healthcare with BFSI nearly 50% of its revenue. (4) The company has a partnership with Oracle in cloud services by providing SLA-based services and operations support (Identity Cloud Service, OCI Cloud Solutions, OCI Core Infrastructure). (5) The acquisition will add ~22% to Happiest Minds' revenue and can scale its BFSI revenue as well as its Healthcare revenue – currently, the BFSI revenue is at USD 21mn and Healthcare revenue is at USD 28mn, both of which will double with the acquisition. (6) PureSoftware's Board includes Anil Baid (Founder and Chief Strategy Officer) and Manish Sharma, CEO since 2016 (earlier VP, Business Head – ASEAN and China at HCL Tech).

Aureus acquisitions: The acquisition rationale is to scale Happiest Minds' BFSI revenue – currently, the Insurance segment is a small component of BFSI. Marquee client access to leading global reinsurers such as Swiss Re and Hannover Re with cross-sell opportunities in IMSS service-line and data & analytics seems to be the rationale.

Key highlights include: (1) Aureus Tech Systems LLC (Aureus) was acquired which is a US-based digital services company with Microsoft expertise largely operating in the Insurance vertical – HAPPSTMN bought 100% in the company (all cash) for USD 8.5mn upfront and a deferred component (up to USD 8.5mn earnout over the next two years). (2) Aureus has 150 employees and revenue of USD 8.3mn (~4% of Happiest Minds revenue) with its revenue CAGR at 22% over CY21-23. (2) Its operating margins are ~20%, supported by 140 employees in its Hyderabad offshore office and ~10 onsite consultants. (3) Aureus' anchor customer is Swiss Re (>70% of Aureus' revenue). (4) Aureus is a Microsoft-certified Gold and co-sell partner and has supported Swiss Re's Corporate Solution business or its commercial insurance arm (CorSo). (5) Aureus has helped in transforming its CRM using Microsoft Azure, integration with Dynamics Marketing. (6) Swiss Re captive in India has 2,000 employees and was set up in 2001 with GBS presence in Hyderabad and Bangalore (there are currently 120 job postings for India GBS of Swiss Re). (7) Swiss Re has also undergone leadership change with CEO transition (group CEO Andreas Berger taking over in July 2024 and India CEO Amitabha Ray appointed in Apr 2024). (8) Key personnel in the company include Abhishek Pakhira-CEO and Debjit Kanjilal-MD (former Swiss Re SVP, Global IT).



Exhibit 1: HAPPSTMN's acquisition history

Year	Acquisitions	Purchase consideration	Services
2024	Aureus	USD 17mn (USD 8.5mn upfront)	Product engineering services - Azure (Insurance & Healthcare) – 150 employees
2024	Pure Software	USD 94mn (USD 77mn upfront)	Digital services (BFSI & Healthcare) – 1,200 employees
2024	Macmillan Learning India	INR 45mn	Software development services/ ODC takeover
2023	SMI (Sri Mookambika Infosolutions)	INR 1.10bn	Product engineering services - 400 employees, Offshore delivery - Madurai/Coimbatore
2021	PGS	USD 8.2mn	Pimcore implementation services
2018	OSS Cube	INR 0.21bn	Consulting & digital services
2018	Cupola Technology	INR 0.07bn	IoT solutions and services

Source: Company, HSIE Research

Exhibit 2: Recent deal wins

Vertical	Deals
Healthcare	build an advanced AI Medical Preventive & Diagnostic solution for MindSculpt Analytics
Healthcare	strategic partnership in engineering and development for mission critical applications
Healthcare	build the asset management platform to provide actionable insights to the field service technicians for MedTech company
BFSI	GenAI solution for training employees on performance management & customer support
Retail	GenAI solution for local language and enterprise knowledge for SE Asia bottler
Hi-Tech	design and configure an end-to-end secure and scalable connected vehicle platform on cloud platform for professional services arm of global hyperscaler
Retail	revamp the User Experience of front facing applications of their Distributed Management Systems for global CPG company
TM&E	provide product engineering services for the Imagineering division of premier entertainment company
TM&E	providing digital transformation services leveraging the Pimcore Platform for global movie chain
Industrial	Strategic partnership to build platform to optimise wind energy generation for Enercon
EduTech	digital engineering services for technology platform
EduTech	build next generation solution for increased engagement and improved efficiency with students and universities

Source: Company, HSIE Research


Exhibit 3: Key Partnerships

Partners	Partnership tiering
AWS	Advanced Consulting Services Partner
Microsoft	Member of the Microsoft AI Cloud Partner Program
Pimcore	Strategic partnership
ServiceNow	Premier managed services partner
Outsystems	Strategic partnership

Source: FY24 Annual Report








Source: Company, HSIE Research

Exhibit 5: Increase in median remuneration and geo mix of employees



Source: Company, HSIE Research

Exhibit 6: Change in estimates

	FY25E	FY25E	Change	FY26E	FY26E	Change
YE Mar (INR bn)	Old	Revised	%	Old	Revised	%
Revenue (USD mn)	262	263	0.4	330	331	0.3
Revenue	21.86	21.95	0.4	28.01	28.09	0.3
EBIT	3.60	3.54	(1.8)	4.86	4.99	2.7
EBIT margin (%)	16.5	16.1	-36bps	17.4	17.8	42 bps
APAT	2.77	2.72	(1.7)	3.70	3.81	2.9
EPS (INR)	18.2	17.9	(1.7)	24.3	25.0	2.9

Source: HSIE Research

Financials

Income Statement

Year ending March (INR bn)	FY21	FY22	FY23	FY24	FY25E	FY26E
Net Sales (USD mn)	104	147	178	196	263	331
Growth (%)	12.2	41.0	21.3	10.3	34.0	25.8
Net Sales	7.73	10.94	14.29	16.25	21.95	28.09
Growth (%)	10.8	41.4	30.7	13.7	35.1	28.0
Employee Expenses	4.52	6.20	8.07	10.15	13.41	17.03
SG&A and Other Operating Expenses	1.30	2.16	2.64	2.74	3.93	4.81
EBIDTA	1.91	2.58	3.59	3.36	4.62	6.25
Depreciation	0.23	0.33	0.42	0.58	1.08	1.26
EBIT	1.69	2.25	3.17	2.78	3.54	4.99
EBIT (%)	21.8	20.6	22.2	17.1	16.1	17.8
EBIT Growth (%)	119.5	33.2	41.0	(12.4)	27.5	41.1
Other Income	0.24	0.31	0.15	0.99	0.55	0.57
Interest	0.07	0.10	0.22	0.42	0.41	0.41
РВТ	1.86	2.46	3.10	3.35	3.68	5.15
Tax (incl deferred)	0.24	0.65	0.79	0.86	0.96	1.34
RPAT	1.62	1.81	2.31	2.48	2.72	3.81
APAT	1.62	1.86	2.36	2.38	2.72	3.81
APAT Growth (%)	96.5	14.3	26.9	1.0	14.4	39.9
EPS (INR)	10.7	12.2	15.5	15.6	17.9	25.0
EPS Growth (%)	96.5	14.3	26.9	1.0	14.4	39.9

Source: Company, HSIE Research

Balance Sheet

balance Sneet						
Year ending March (INR bn)	FY21	FY22	FY23	FY24	FY25E	FY26E
SOURCES OF FUNDS						
Share Capital - Equity	0.28	0.29	0.29	0.30	0.30	0.30
Reserves	5.18	6.37	8.10	14.50	16.20	18.64
Total Shareholders' Funds	5.46	6.66	8.39	14.80	16.50	18.94
Total Debt	1.46	1.91	4.68	4.42	4.42	4.42
Net Deferred Taxes	(0.03)	(0.02)	0.08	(0.03)	(0.03)	(0.03)
Long Term Provisions & Others	0.53	0.70	0.92	0.83	0.83	0.83
TOTAL SOURCES OF FUNDS	7.43	9.24	14.07	20.02	21.72	24.16
APPLICATION OF FUNDS						
Net Block	0.52	0.79	2.93	2.73	5.40	5.92
CWIP	0.00	0.00	0.02	0.00	0.00	0.00
Goodwill	0.76	0.79	1.39	1.40	6.92	6.92
Other non-current assets	0.39	0.33	1.21	0.40	0.40	0.40
Total Non-Current Assets	1.67	1.91	5.55	4.54	12.73	13.25
Cash & Equivalents	5.37	6.32	6.92	13.37	5.92	6.83
Debtors	1.22	1.67	2.13	2.54	3.44	4.40
Other Current Assets	0.86	1.28	1.68	1.87	2.42	3.01
Total Current Assets	2.08	2.95	3.81	4.41	5.86	7.41
Creditors	0.41	0.61	0.71	0.79	1.06	1.36
Other Current Liabilities & Provns	1.28	1.33	1.51	1.50	1.72	1.97
Total Current Liabilities	1.69	1.94	2.22	2.29	2.79	3.33
Net Current Assets	0.39	1.02	1.60	2.12	3.07	4.09
TOTAL APPLICATION OF FUNDS	7.43	9.24	14.07	20.02	21.72	24.16

Source: Company, HSIE Research

Cash Flow

Year ending March (INR bn)	FY21	FY22	FY23	FY24	FY25E	FY26E
Reported PBT	1.86	2.46	3.10	3.35	3.68	5.15
Non-operating & EO items	(0.07)	(0.12)	(0.15)	(0.90)	(0.41)	(0.42)
Interest expenses	0.07	0.10	0.22	0.42	0.41	0.41
Depreciation	0.23	0.33	0.42	0.58	1.08	1.26
Working Capital Change	(0.29)	(0.55)	(0.63)	(0.31)	(0.95)	(1.02)
Tax paid	(0.36)	(0.53)	(0.89)	(1.02)	(0.96)	(1.34)
OPERATING CASH FLOW (a)	1.44	1.68	2.07	2.13	2.86	4.05
Capex	(0.01)	(0.04)	(1.39)	(0.10)	(9.28)	(1.78)
Free cash flow (FCF)	1.43	1.64	0.68	2.02	(6.42)	2.27
Investments	(2.83)	(0.84)	(2.03)	(4.56)	-	-
Non-operating income	-	-	-	-	0.41	0.42
INVESTING CASH FLOW (b)	(2.84)	(0.88)	(3.43)	(4.66)	(8.87)	(1.36)
Debt Issuance	0.67	(0.21)	(0.26)	(0.85)	-	-
Interest expenses	(0.04)	(0.03)	(0.15)	(0.33)	(0.41)	(0.41)
FCFE	2.06	1.40	0.27	0.84	(6.83)	1.86
Share capital Issuance	1.06	0.02	0.01	0.02	0.01	-
Dividend/buyback	-	(0.68)	(0.57)	(0.86)	(1.03)	(1.37)
FINANCING CASH FLOW (c)	1.69	(0.91)	(0.97)	(2.02)	(1.44)	(1.78)
NET CASH FLOW (a+b+c)	0.29	(0.11)	(2.32)	(4.56)	(7.44)	0.91
Non-operating and EO items	3.80	1.06	2.92	11.01	-	-
Closing Cash & Equivalents	5.37	6.32	6.92	13.37	5.92	6.83


Source: Company, HSIE Research

Key Ratios

	FY21	FY22	FY23	FY24	FY25E	FY26E
PROFITABILITY (%)						
GPM	41.5	43.3	43.6	37.5	38.9	39.4
EBITDA Margin	24.8	23.6	25.1	20.7	21.0	22.3
APAT Margin	21.0	17.0	16.5	14.6	12.4	13.6
RoE	40.0	30.6	31.3	20.5	17.4	21.5
RoIC (or Core RoCE)	66.3	66.5	46.9	29.8	23.3	22.3
RoCE	30.4	23.2	21.6	15.8	14.5	17.9
EFFICIENCY						
Tax Rate (%)	12.7	26.3	25.5	25.8	26.0	26.0
Fixed Asset Turnover (x)	NA	NA	7.4	7.9	9.0	9.7
Debtors (days)	58	56	54	57	57	57
Other Current Assets (days)	41	43	43	42	40	39
Payables (days)	19	20	18	18	18	18
Other Current Liab & Provns (days)	60	44	39	34	29	26
Cash Conversion Cycle (days)	18	34	41	48	51	53
Debt/EBITDA (x)	0.8	0.7	1.3	1.3	1.0	0.7
Net D/E (x)	(0.7)	(0.7)	(0.3)	(0.6)	(0.1)	(0.1)
Interest Coverage (x)	24	23	14	7	9	12
PER SHARE DATA (INR)						
EPS	10.7	12.2	15.5	15.6	17.9	25.0
CEPS	12.2	15.0	19.1	19.5	25.0	33.3
Dividend	3.0	3.8	5.4	5.8	6.8	9.0
Book Value	36	46	58	97	108	124
VALUATION						
P/E (x)	82.9	72.5	57.1	56.6	49.4	35.3
P/BV (x)	24.7	19.3	15.3	9.1	8.2	7.1
EV/EBITDA (x)	68.3	50.5	36.9	37.4	28.8	21.1
EV/Revenues (x)	16.9	11.9	9.3	7.7	6.1	4.7
OCF/EV (%)	1.1	1.3	1.6	1.7	2.1	3.1
FCF/EV (%)	1.1	1.3	0.5	1.6	(4.8)	1.7
FCFE/Mkt Cap (%)	1.5	1.1	0.2	0.6	(5.1)	1.4
Dividend Yield (%)	0.3	0.4	0.6	0.7	0.8	1.0

Source: Company, HSIE Research





Disclosure:

We, **Apurva Prasad**, **MBA**, **Amit Chandra**, **MBA & Vinesh Vala**, **MBA** authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. SEBI conducted the inspection and based on their observations have issued advise/warning. The said observations have been complied with. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does have/does not have any material conflict of interest.

Any holding in stock – No

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

Please note that HDFC Securities has a proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Murli V Karkera Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

For grievance redressal contact Customer Care Team Email: customercare@hdfcsec.com Phone: (022) 3901 9400

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.